Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients

Michael Davidson*, Miklos F. Losonczy, Richard C. Mohs, Juliet C. Lesser, Peter Powchik, Linda B. Freed, Bonnie M. Davis, Victoria V. Mykytyn, Kenneth L. Davis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Plasma levels of the dopamine metabolite homovanillic acid (pHVA) may potentially reflect upon central dopamine activity. This study examines the effects of debrisoquin, haloperidol, and the two drugs combined on pHVA concentrations of schizophrenic patients. Debrisoquin is a drug that suppresses the peripheral formation of homovanillic acid without affecting the central formation. Acute haloperidol administration consistently increased pHVA concentrations in patients pretreated or not pretreated with debrisoquin, suggesting that this increment reflects haloperidol's central and not peripheral effects.

Original languageEnglish
Pages (from-to)17-23
Number of pages7
JournalNeuropsychopharmacology
Volume1
Issue number1
DOIs
StatePublished - Dec 1987
Externally publishedYes

Keywords

  • Debrisoquin
  • Haloperidol
  • Homovanillic acid
  • Schizophrenia

Fingerprint

Dive into the research topics of 'Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients'. Together they form a unique fingerprint.

Cite this